» Articles » PMID: 34697721

Can Soluble Immune Checkpoint Molecules on Exosomes Mediate Inflammation?

Overview
Date 2021 Oct 26
PMID 34697721
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Immune checkpoints (ICPs) are major co-signaling pathways that trigger effector functions in immune cells, with isoforms that are either membrane bound, engaging in direct cell to cell activation locally, or soluble, acting at distant sites by circulating freely or potentially via extracellular vesicles (EVs). Exosomes are small EVs secreted by a variety of cells carrying various proteins and nucleic acids. They are distributed extensively through biological fluids and have major impacts on infectious diseases, cancer, and neuroinflammation. Similarly, ICPs play key roles in a variety of disease conditions and have been extensively utilized as a prognostic tool for various cancers. Herein, we explored if the association between exosomes and ICPs could be a significant contributor of inflammation, particularly in the setting of cancer, neuroinflammation and viral infections, wherein the up regulation in both exosomal proteins and ICPs correlate with immunosuppressive effects. The detailed literature review of existing data highlights the significance and complexity of these two important pathways in mediating cancer and potentiating neuroinflammation via modulating overall immune response. Cells increasingly secret exosomes in response to intracellular signals from invading pathogens or cancerous transformations. These exosomes can carry a variety of cargo including proteins, nucleic acids, cytokines, and receptors/ligands that have functional consequences on recipient cells. Illustration generated using BioRender software.

Citing Articles

Predicting survival in patients with SARS-CoV-2 based on cytokines and soluble immune checkpoint regulators.

Lee N, Jeon K, Park M, Song W, Jeong S Front Cell Infect Microbiol. 2024; 14:1397297.

PMID: 39654974 PMC: 11625743. DOI: 10.3389/fcimb.2024.1397297.


Extracellular vesicles: immunomodulation, diagnosis, and promising therapeutic roles for rheumatoid arthritis.

Abebaw D, Akelew Y, Adugna A, Teffera Z, Tegegne B, Fenta A Front Immunol. 2024; 15:1499929.

PMID: 39624102 PMC: 11609219. DOI: 10.3389/fimmu.2024.1499929.


Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality?.

Brugiapaglia S, Spagnolo F, Intonti S, Novelli F, Curcio C Cells. 2024; 13(18.

PMID: 39329742 PMC: 11430323. DOI: 10.3390/cells13181558.


Exploring the potential of the convergence between extracellular vesicles and CAR technology as a novel immunotherapy approach.

Bar O, Porgador A, Cooks T J Extracell Biol. 2024; 3(9):e70011.

PMID: 39328262 PMC: 11424882. DOI: 10.1002/jex2.70011.


Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies.

Pitts S, Schlom J, Donahue R J Exp Clin Cancer Res. 2024; 43(1):155.

PMID: 38822401 PMC: 11141022. DOI: 10.1186/s13046-024-03074-z.


References
1.
Odagiri N, Hai H, Thuy L, Dong M, Suoh M, Kotani K . Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization. Cancers (Basel). 2020; 12(8). PMC: 7464181. DOI: 10.3390/cancers12082045. View

2.
Skryabin G, Komelkov A, Savelyeva E, Tchevkina E . Lipid Rafts in Exosome Biogenesis. Biochemistry (Mosc). 2020; 85(2):177-191. DOI: 10.1134/S0006297920020054. View

3.
Emmanouilidi A, Paladin D, Greening D, Falasca M . Oncogenic and Non-Malignant Pancreatic Exosome Cargo Reveal Distinct Expression of Oncogenic and Prognostic Factors Involved in Tumor Invasion and Metastasis. Proteomics. 2019; 19(8):e1800158. DOI: 10.1002/pmic.201800158. View

4.
Gupta A, Pulliam L . Exosomes as mediators of neuroinflammation. J Neuroinflammation. 2014; 11:68. PMC: 3994210. DOI: 10.1186/1742-2094-11-68. View

5.
Skog J, Wurdinger T, van Rijn S, Meijer D, Gainche L, Sena-Esteves M . Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12):1470-6. PMC: 3423894. DOI: 10.1038/ncb1800. View